Research shows that tens of millions of Americans use cannabis: Among adults age 19 to 30, about 42 percent reported cannabis use during the past year, and levels reached 29 percent among those age 35 to 50, according to a 2023 survey funded by the National Institutes of Health. Yet science that should guide how cannabis is used lags behind real-world practice, leaving patients and health care providers to make decisions without the level of evidence that is standard for other treatments. This gap is particularly troubling in areas such as chronic pain management, mental health, and sleep, as patients may substitute cannabis for more established therapies without medical guidance.​

Despite its unmatched concentration of academic medical centers and research universities, Massachusetts is no longer at the forefront of medical cannabis research. States such as Pennsylvania have established formal partnerships among regulators, universities, and licensees to study conditions including cancer, epilepsy, chronic pain, and opioid reduction, embedding research protocols directly into their medical cannabis programs. As a result of the lack of research in Massachusetts, patients here often rely on products and regimens that have not been evaluated with the rigor expected in the health care system.​

The Massachusetts Cannabis Control Commission plays a leading role as a widely respected voice on cannabis research and regulatory policy. Building on that role, commission leaders are working with stakeholders including other cannabis regulators, academic and industry researchers, and the University of Massachusetts to define a vision for a multidisciplinary Center for Cannabis Research and Policy that would unite social policy research with biomedical and clinical studies to assess how cannabis affects human health across populations.

The Legislature showed foresight in 2017 in directing the commission to produce an annual research report on the health and social impacts of cannabis, providing policy makers with evidence to better protect Massachusetts citizens. Commissioners are pursuing a review to streamline regulations that disincentivize serious research investment into the effects of cannabis.​

The proposed Center for Cannabis Research and Policy would serve as a statewide hub connecting public agencies, academic medical centers, and licensed operators. The commission has won numerous research grants, but as an independent government agency, it currently lacks a financial mechanism under state law allowing it to accept these funds.

The new center could allow the state to accept significant funds to research veterans’ health, epilepsy, chronic pain, and opioid tapering, while developing shared data standards so findings generated in Massachusetts could inform clinicians nationally and influence regulatory practice. In doing so, the center would position cannabis research not only as a driver of scientific innovation but also as a tool to advance safety, equity, and economic opportunity.​

The University of Massachusetts Amherst, the Commonwealth’s flagship public research university, is uniquely suited to play a significant role in moving cannabis research forward. UMass has a diverse and nationally recognized research enterprise and a mission of supporting the needs of the Commonwealth through education, research, and service that dates back to the university’s founding in 1863.

UMass Amherst already conducts a variety of cannabis research, including research on public health, policy, and the economic impacts of legalization. Given the university’s long history of pursuing a US Drug Enforcement Administration research license, this alignment of mission, capacity, and regulatory readiness would make UMass Amherst the ideal partner to help Massachusetts reestablish its leadership in evidence-based cannabis research.

As federal policy evolves and rescheduling moves forward, jurisdictions generating credible research evidence will shape clinical guidelines, insurance coverage, and international standards for cannabis-based therapies. Massachusetts has the infrastructure to become a regional, national, and global leader in cannabis medicine and policy, but that outcome is not guaranteed; it will require intentional investment, coordinated governance, and a clear decision to lead at this historic moment.​